These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 28668350)
1. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. Laing AA; Harrison CJ; Gibson BES; Keeshan K Exp Hematol; 2017 Oct; 54():40-50. PubMed ID: 28668350 [TBL] [Abstract][Full Text] [Related]
2. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Laszlo GS; Estey EH; Walter RB Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231 [TBL] [Abstract][Full Text] [Related]
3. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031 [TBL] [Abstract][Full Text] [Related]
4. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813 [TBL] [Abstract][Full Text] [Related]
5. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Laszlo GS; Harrington KH; Gudgeon CJ; Beddoe ME; Fitzgibbon MP; Ries RE; Lamba JK; McIntosh MW; Meshinchi S; Walter RB Oncotarget; 2016 Jul; 7(28):43281-43294. PubMed ID: 27248327 [TBL] [Abstract][Full Text] [Related]
6. CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML). Jiang Y; Xu P; Yao D; Chen X; Dai H Med Sci Monit; 2017 Apr; 23():1725-1732. PubMed ID: 28391288 [TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia fusion genes can be found in CD33-negative cells. Chen Y; Liu Q; Xing H; Rao Q; Wang M; Mi Y; Wei H; Wang J Int J Lab Hematol; 2022 Dec; 44(6):1111-1114. PubMed ID: 35915999 [TBL] [Abstract][Full Text] [Related]
10. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Willier S; Rothämel P; Hastreiter M; Wilhelm J; Stenger D; Blaeschke F; Rohlfs M; Kaeuferle T; Schmid I; Albert MH; Binder V; Subklewe M; Klein C; Feuchtinger T Blood; 2021 Feb; 137(8):1037-1049. PubMed ID: 33094319 [TBL] [Abstract][Full Text] [Related]
11. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia. Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1. Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889 [TBL] [Abstract][Full Text] [Related]
14. How I treat acute myeloid leukemia in the era of new drugs. DiNardo CD; Wei AH Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470 [TBL] [Abstract][Full Text] [Related]
15. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817 [TBL] [Abstract][Full Text] [Related]
16. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365 [TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Walter RB; Appelbaum FR; Estey EH; Bernstein ID Blood; 2012 Jun; 119(26):6198-208. PubMed ID: 22286199 [TBL] [Abstract][Full Text] [Related]
18. CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents. Papageorgiou I; Loken MR; Brodersen LE; Gbadamosi M; Uy GL; Meshinchi S; Lamba JK Leuk Lymphoma; 2019 Sep; 60(9):2287-2290. PubMed ID: 30721105 [No Abstract] [Full Text] [Related]
19. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia. Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332 [TBL] [Abstract][Full Text] [Related]
20. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells. Pelosi E; Castelli G; Testa U Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]